Summary
Becton Dickinson & Co. (BDX) reported solid revenue growth for the third quarter and the first nine months of fiscal year 2011, driven by strong performance in its Medical and Diagnostics segments, particularly in international markets and emerging economies. Despite a challenging global economic environment and some headwinds from healthcare austerity measures in Western Europe, the company demonstrated resilience with a 10% increase in third-quarter revenues to $2.014 billion and a 5% increase for the nine-month period to $5.778 billion. This growth was supported by favorable foreign currency translation, which partially offset price decreases. The company maintained strong operational cash flows, enabling significant investments in share repurchases and dividends, alongside strategic acquisitions. The acquisition of Accuri Cytometers, Inc. in March 2011 is expected to bolster the Biosciences segment. While the company faces ongoing litigation risks and potential impacts from the U.S. healthcare reform, its diversified business model and international presence position it favorably for continued growth.
Financial Highlights
50 data points| Revenue | $1.95B |
| Cost of Revenue | $922.65M |
| Gross Profit | $1.03B |
| R&D Expenses | $114.08M |
| SG&A Expenses | $467.97M |
| Operating Expenses | $1.50B |
| Operating Income | $447.19M |
| Interest Expense | $22.21M |
| Net Income | $343.06M |
| EPS (Basic) | $1.57 |
| EPS (Diluted) | $1.53 |
| Shares Outstanding (Basic) | 218.97M |
| Shares Outstanding (Diluted) | 223.57M |
Key Highlights
- 1Revenue increased by 10% to $2.014 billion in the third quarter of fiscal year 2011, with international sales showing particular strength.
- 2Net income for the quarter rose to $343 million, an increase from $307 million in the prior year's quarter, with diluted EPS at $1.53.
- 3The company acquired Accuri Cytometers, Inc. for $205 million to expand its presence in personal flow cytometers within the Biosciences segment.
- 4Significant capital allocation towards returning value to shareholders, with $1.273 billion in stock repurchases and $273 million in dividends paid during the first nine months of fiscal year 2011.
- 5Long-term debt increased significantly due to the issuance of $1 billion in notes in November 2010, aimed at funding general corporate purposes.
- 6The Medical segment showed robust growth, driven by Pharmaceutical Systems and safety-engineered products, with operating income increasing by 10.5%.
- 7The company is actively managing legal proceedings, including ongoing antitrust litigation and patent infringement cases, with some recent developments in appeals and court decisions.